- Home
- KEY vs WST Comparison
KEY vs WST Comparison
Compare KEY & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | WST |
|---|---|---|
| Founded | 1825 | 1923 |
| Country | United States | United States |
| Employees | 17883 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 18.5B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | KEY | WST |
|---|---|---|
| Price | $21.09 | $304.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $22.90 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 9.8M | 927.7K |
| Earning Date | 04-16-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.78% | 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.92 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $15.33 | $6.76 |
| Revenue Next Year | $6.06 | $6.22 |
| P/E Ratio | ★ $14.43 | $158.44 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $15.28 | $203.74 |
| 52 Week High | $23.35 | $330.88 |
Technical Indicators
Market Signals| Indicator | KEY | WST |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 57.64 |
| Support Level | $20.33 | $259.17 |
| Resistance Level | $21.25 | $321.34 |
| Average True Range (ATR) | 0.42 | 8.89 |
| MACD | -0.15 | -2.40 |
| Stochastic Oscillator | 22.19 | 32.54 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 15 states, but it is predominantly concentrated in its three largest markets: Ohio, New York, and Washington. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.